Company Overview and News

 
PTGX / Protagonist Therapeutics, Inc. S-3

2018-09-07 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS
PTGX

 
PTGX / Protagonist Therapeutics, Inc. / FARALLON CAPITAL MANAGEMENT LLC - null (Passive Investment)

2018-08-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PTGX

 
PTGX / Protagonist Therapeutics, Inc. / FARALLON CAPITAL MANAGEMENT LLC - null (Passive Investment)

2018-08-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PTGX

 
PTGX / Protagonist Therapeutics, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G (Passive Investment)

2018-08-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PTGX

 
PTGX / Protagonist Therapeutics, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G (Passive Investment)

2018-08-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PTGX

3
Protagonist Stock Jumps 58% After Re-Review of Test Results

2018-08-08 investorplace
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. The rally is a welcome change after months of PTGX stock going nowhere.
PFZ CELG PTGX 500680 PFE PFIZER

30
Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down

2018-08-08 seekingalpha - 2
Discussion: Foundation Medicine’s (FMI) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis of more than one thousand samples from NSCLC patients who participated in Roche (OTCQX:RHHBY) Genetech’s trials showed that use of Foundation Medicine’s (FMI) blood tumor mutational burden (‘bTMB) assay would have helped predict responses to TECENTRIQ (atezolizumab).
INO GILD PRTK TEVA OVID TEVVF ELTP SSKN PTIE MELA TEVJF EIGR PTGX FMI PFE

 
PTGX / Protagonist Therapeutics, Inc. 8-K (Current Report)

2018-08-08 sec.gov
PTGX_Current_Folio_8K UNITED STATES
PTGX

 
PTGX / Protagonist Therapeutics, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
ptgx_Current_Folio_10Q Table of Contents
PTGX

 
PTGX / Protagonist Therapeutics, Inc. 424B5 (Prospectus)

2018-08-07 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
PTGX

 
Why Protagonist Therapeutics Is Getting a Second Chance

2018-08-06 247wallst
Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares saw a solid gain on Monday after the firm announced positive results from its midstage trial in patients with ulcerative colitis. This comes after some controversy within the study earlier this year.
PTGX

2
Protagonist Therapeutics: A Golden Opportunity Trading At A Silver Price

2018-07-23 seekingalpha
Many investors were spooked by the PTG-100 failure. However, the results of PTG-100 are unlikely to be predictive of other programs.
MOR CELG PTGX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 74366E102